A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
46
Participants
Timeline
Start Date
June 30, 2014
Primary Completion Date
October 31, 2014
Study Completion Date
December 31, 2014
Conditions
Healthy
Interventions
DRUG
UI15AML055MT
tab, PO
DRUG
Amosartan 5/50
tab, PO
Trial Locations (1)
110-744
Seoul National University Hospital, Seoul
All Listed Sponsors
lead
Korea United Pharm. Inc.
INDUSTRY
NCT02166398 - A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter